Peter Thiel-backed psychedelic drug maker aims to raise $100M in IPO

Psychedelic drugmaker ATAI Life Science, which backed by billionaire investor Peter Thiel, said it is planning to raise $100 million in an initial public offering. The Berlin-based company — which tests drugs like ketamine, DMT and psilocybin, the active ingredient in “magic mushrooms,” to treat depression — raised an aggregate of $362.3 million from private… Continue reading at New York Post